Market Overview:
The global glaucoma drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of glaucoma, rising awareness about glaucoma and its treatment options, and the launch of new products. The global glaucoma drugs market is segmented on the basis of type into prostaglandin analogs (PGAs), beta blocker, alpha agonist, and others. The prostaglandin analogs segment is expected to dominate the global glaucoma drugs market during the forecast period owing to their high efficacy in reducing intraocular pressure (IOP) levels. On the basis of application, the global glaucoma drugs market is segmented into clinics, pharmacies, and other applications.
Product Definition:
Glaucoma drugs are used to treat high eye pressure, which is a common symptom of glaucoma. These medications help to lower the pressure in the eyes by either decreasing the production of fluid or increasing the drainage of fluid.
Prostaglandin Analogs (PGAs):
Prostaglandin analogs (PGAs) are a class of drugs that act by increasing the flow of fluid out of the eyes. They do this by opening certain pathways in the brain, which causes an increase in pressure inside the eye. This increases fluid flow out of the eye and reduces pressure inside it, thus lowering its content.
Beta Blocker:
Beta blockers are the first line of treatment for glaucoma. They reduce intraocular pressure by decreasing the rate of formation of aqueous fluid and prevent further damage to the nerve that supplies the eye with water. The most commonly used drugs are atenolol, propranolol, sertindole, and timolol.
Application Insights:
The other application segment includes Ophthalmic Gel, Ointment and Spray. The ophthalmic gels accounted for the largest share in 2017 owing to its wide usage as a topical anesthetic agent for glaucoma surgery. The ointments are expected to be the fastest-growing segment over the forecast period due to their high convenience and effectiveness.
Glaucoma drugs are used in various applications such as acute angle-closure glaucoma (AACG), open-angle glaucoma (OAG), chronic idiopathic primary anterior chamber opacity (CIPACO) and others. In 2017, OAG held the largest market share of around 60% among all types of glaucomas while AACG held around 20%. However, CIPACO is expected to grow at a faster rate than other types of glaucomas during the forecast period due to its low incidence rate compared with that of OAG or AACG.
Regional Analysis:
North America held the largest share of global market in 2017. The region is expected to maintain its dominance during the forecast period due to rising cases of glaucoma, increasing awareness about treatment options, and availability of advanced products. Moreover, presence of key players such as Bausch & Lomb; and EyeMed Vision Care will also boost the growth in this region.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to high unmet clinical needs coupled with huge target population base in emerging economies such as China and India. Furthermore, growing medical tourism industry will also drive regional growth during future years.
Growth Factors:
- Increasing prevalence of glaucoma: Glaucoma is a leading cause of blindness, and the number of people affected by the disease is increasing every year. This will drive the demand for glaucoma drugs in the coming years.
- Growing awareness about glaucoma: There is a growing awareness about glaucoma among people around the world, which is driving them to seek treatment for the disease. This will create opportunities for growth in the global glaucoma drugs market.
- Technological advancements: The development of new and innovative technologies has led to better diagnosis and treatment options for patients with glaucoma, thereby boosting growth prospects for this market segment.
- Rising incidence of eye-related disorders: The incidence of other eye-related disorders such as cataract, age-related macular degeneration (AMD), and diabetic retinopathy is rising at an alarming rate across the globe due to changing lifestyles and population demographics. This will create opportunities for growth in both segments of the global Glaucomas Drugs market – namely prescription drugs and over-the-counter (OTC) products . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Glaucoma Drugs Market Research Report
By Type
Prostaglandin Analogs (PGAs), Beta Blocker, Alpha Agonist, Others
By Application
Clinic, Pharmacy, Other
By Companies
Novartis, Allergan, Pfizer, Akorn, Teva, Bausch & Lomb, Otsuka Pharmaceutical, Santen, Lunan Pharma, Zizhu Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Glaucoma Drugs Market Report Segments:
The global Glaucoma Drugs market is segmented on the basis of:
Types
Prostaglandin Analogs (PGAs), Beta Blocker, Alpha Agonist, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Allergan
- Pfizer
- Akorn
- Teva
- Bausch & Lomb
- Otsuka Pharmaceutical
- Santen
- Lunan Pharma
- Zizhu Pharma
Highlights of The Glaucoma Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostaglandin Analogs (PGAs)
- Beta Blocker
- Alpha Agonist
- Others
- By Application:
- Clinic
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glaucoma Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glaucoma drugs are medications that are used to lower the pressure in the eye. This can help to prevent damage to the optic nerve and blindness.
Some of the key players operating in the glaucoma drugs market are Novartis, Allergan, Pfizer, Akorn, Teva, Bausch & Lomb, Otsuka Pharmaceutical, Santen, Lunan Pharma, Zizhu Pharma.
The glaucoma drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glaucoma Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glaucoma Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glaucoma Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glaucoma Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glaucoma Drugs Market Size & Forecast, 2020-2028
4.5.1 Glaucoma Drugs Market Size and Y-o-Y Growth
4.5.2 Glaucoma Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Prostaglandin Analogs (PGAs)
5.2.2 Beta Blocker
5.2.3 Alpha Agonist
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glaucoma Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glaucoma Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Prostaglandin Analogs (PGAs)
9.6.2 Beta Blocker
9.6.3 Alpha Agonist
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Prostaglandin Analogs (PGAs)
10.6.2 Beta Blocker
10.6.3 Alpha Agonist
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Prostaglandin Analogs (PGAs)
11.6.2 Beta Blocker
11.6.3 Alpha Agonist
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Prostaglandin Analogs (PGAs)
12.6.2 Beta Blocker
12.6.3 Alpha Agonist
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Prostaglandin Analogs (PGAs)
13.6.2 Beta Blocker
13.6.3 Alpha Agonist
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glaucoma Drugs Market: Competitive Dashboard
14.2 Global Glaucoma Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Allergan
14.3.3 Pfizer
14.3.4 Akorn
14.3.5 Teva
14.3.6 Bausch & Lomb
14.3.7 Otsuka Pharmaceutical
14.3.8 Santen
14.3.9 Lunan Pharma
14.3.10 Zizhu Pharma
